<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0001045'>vitiligo</z:hpo> have circulating antibodies to melanocytes </plain></SENT>
<SENT sid="1" pm="."><plain>To identify <z:hpo ids='HP_0001045'>vitiligo</z:hpo> antibodies and characterize the antigens by <z:hpo ids='HP_0001045'>vitiligo</z:hpo> antibodies, sera of 18 patients with <z:hpo ids='HP_0001045'>vitiligo</z:hpo>, 18 with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e>, 22 with <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> and 14 <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects were analyzed by indirect immunofluorescence, live cell ELISA, and immunoblotting </plain></SENT>
<SENT sid="2" pm="."><plain>In indirect immunofluorescent microscopy and live cell ELISA, most <z:hpo ids='HP_0001045'>vitiligo</z:hpo> sera showed positive immunofluorescence and high optical density on the surface of melanocytes cultured from <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:hpo ids='HP_0001045'>vitiligo</z:hpo> patients, indicating that autoantibodies in the <z:hpo ids='HP_0001045'>vitiligo</z:hpo> sera may react with <z:hpo ids='HP_0001045'>vitiligo</z:hpo> antigens on the surface of melanocytes </plain></SENT>
<SENT sid="3" pm="."><plain>When the same experiments were performed with <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> cell lines and fibroblasts, no significant differences in the immunofluorescence and optical density were observed between <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:hpo ids='HP_0001045'>vitiligo</z:hpo> sera </plain></SENT>
<SENT sid="4" pm="."><plain>And the sera of patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> or <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> showed no significant difference in the reaction of live cell ELISA to fibroblasts, IGR-3 and melanocytes </plain></SENT>
<SENT sid="5" pm="."><plain>The antibody titers of <z:hpo ids='HP_0001045'>vitiligo</z:hpo> patients in live cell ELISA decreased following systemic steroid treatments </plain></SENT>
<SENT sid="6" pm="."><plain>Immunoblot analysis demonstrated that 44% of <z:hpo ids='HP_0001045'>vitiligo</z:hpo> sera was directed to melanocyte antigen with a molecular weight of 65 kDa </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibition assay using rabbit anti-melanocyte antibody showed inhibition of reaction between <z:hpo ids='HP_0001045'>vitiligo</z:hpo> sera and melanocytes in ELISA and immunoblotting </plain></SENT>
<SENT sid="8" pm="."><plain>These findings support the hypothesis that the sera of <z:hpo ids='HP_0001045'>vitiligo</z:hpo> patients have autoantibodies mostly directed to the 65-kDa antigen and this antigen may originate mostly from the melanocyte surface </plain></SENT>
</text></document>